You have permission to edit this article. Edit Close Activate Subscribe My Account Logout Login/Register ...

SAN FRANCISCO, May 6, 2025 /PRNewswire/ -- Perfuse Therapeutics, Inc. ("Perfuse Therapeutics"), a biopharmaceutical company pioneering transformational therapies to treat ischemia-induced ocular ...

("Perfuse Therapeutics"), a biopharmaceutical company pioneering transformational therapies to treat ischemia-induced ocular diseases, today announced positive 24-week results from its completed ...

14.0 35.6 59.1 (23.5) - ST / 1000 m / tf / 9 bt 10 / H Bowman / Swimming ...

SAN FRANCISCO, May 6, 2025 /PRNewswire/ -- Perfuse Therapeutics, Inc. ("Perfuse Therapeutics"), a biopharmaceutical company pioneering transformational therapies to treat ischemia-induced ocular ...

“Our mission is to develop the first disease-modifying treatment for glaucoma, the leading cause of irreversible global blindness with no approved therapies,” said Sevgi Gurkan, MD, CEO and founder of ...